l General Information |
Product Name | Nilutamide |
General description | Nilutamide is a nonsteroidal antiandrogen (NSAA) with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). It is used in the treatment of prostate cancer. |
Synonym | RU23908; 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione |
Purity | ≥98.0%(HPLC) | CAS Number | 63612-50-0 |
Formula | C12H10F3N3O4 | Molecular Weight | 317.22 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | Off-white powder |
Solubility(25°C) | DMSO | ≥45mg/ml |
Ethanol | ≥45mg/ml |
Water | Insoluble |
l Biological Information |
Biochem/Physiol
Actions | Nilutamide is a synthetic, nonsteroidal agent with antiandrogenic properties. Nilutamide preferentially binds to androgen receptors and blocks androgen receptor activation by testosterone and other androgens; this agent may inhibit androgen dependent growth of normal and neoplastic prostate cells. |
l Storage |
Storage temp. | -20°C |
l Precautions and Disclaimer |
This product is for R&D use only, not
for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
